Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Nahla M. Heikal"'
Autor:
Adam J. Kanack, Curtis G. Jones, Bandana Singh, Rachel R. Leger, Noah P. Splinter, Nahla M. Heikal, Rajiv K. Pruthi, Dong Chen, Gemlyn George, Mouhamed Y. Abou-Ismail, Geoffrey D. Wool, Krishna Gundabolu, Anand Padmanabhan
Publikováno v:
Blood. 140:2722-2729
Heparin-induced thrombocytopenia (HIT) is suspected much more often than it is confirmed. Technically simple platelet factor 4 (PF4)-polyanion enzyme-linked immunosorbent assays (ELISAs) are sensitive but nonspecific. In contrast, accurate functional
Autor:
Rohan Willis, Nahla M. Heikal, Thomas B. Martins, Jason Miller, Robert L. Schmidt, Anne E. Tebo
Publikováno v:
Clinica Chimica Acta. 485:7-13
Background We assessed the performance characteristics and correlations of the traditional enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassay (CIA) for detecting IgG and IgM antibodies to cardiolipin (aCL) and beta2 glycoprot
Autor:
Nahla M. Heikal, Dong Chen, Jansen N. Seheult, Julie I. Tange, Laynalee K. Cardel, William L. Nichols, Aneel A. Ashrani
Publikováno v:
American journal of clinical pathology. 154(5)
Objectives Despite more than 40 years of experience performing the Bethesda assay (BA), poor intra- and interlaboratory precision remains the biggest laboratory challenge to date. Methods The BA procedure was modeled using stochastic simulation techn
Autor:
Sabina Swierczek, Mohamed E. Salama, Nahla M. Heikal, Soo Jin Kim, Scott Litton, Jihyun Song, Kim Hickman, Katherine Y. King, Tsewang Tashi, Josef T. Prchal
Publikováno v:
Leukemia. 32:1830-1833
Autor:
Anand Padmanabhan, Rachel Leger, Abdulrahman Saadalla, Aneel A. Ashrani, Dong Chen, Rajiv K. Pruthi, Nahla M. Heikal
Publikováno v:
Blood. 138:3228-3228
Introduction: Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening condition that could occur following exposure to heparin. Accurate and timely diagnosis is critical for appropriate clinical management. Laboratory testing for sus
Autor:
Nahla M. Heikal, Anand Padmanabhan, Rachel Leger, Rajiv K. Pruthi, Dong Chen, Abdulrahman Saadalla, Aneel A. Ashrani
Publikováno v:
Blood. 138:3227-3227
Background: Heparin induced thrombocytopenia (HIT) is a rare immune mediated complication that is triggered in a subset of patients temporal to therapeutic heparin exposure. Laboratory testing is based on screening for the presence of serum anti-PF4
Autor:
Caleb Scheckel, Dong Chen, Aneel A. Ashrani, Nahla M. Heikal, Ariela L. Marshall, Rajiv K. Pruthi
Publikováno v:
Blood. 136:39-40
Introduction: The 2013 ASH Choosing Wisely campaign recommends against thrombophilia testing in patients with major transient risk factors for venous thromboembolism (VTE). Our Special Coagulation Laboratory (SCL) offers an algorithmic approach to th
Autor:
Nahla M. Heikal, Meera Sridharan, Ann M. Moyer, Cheryl L. Tran, Jeffrey L. Winters, Ronald S. Go, Christianne Bourlon De Los Rios, Hassan B. Alkhateeb, Nelson Leung, Aldo A. Acosta-Medina, Dong Chen, Maria Alice V. Willrich, Ariela L. Marshall, Fernando C. Fervenza
Publikováno v:
Blood. 136:25-26
Background Eculizumab, a monoclonal antibody targeting C5, is an effective treatment for complement-mediated thrombotic microangiopathy (CM-TMA), also known as atypical hemolytic uremic syndrome. Although lifelong therapy has been suggested, the opti
Autor:
Ariela L. Marshall, Dong Chen, Nahla M. Heikal, Rajiv K. Pruthi, Aneel A. Ashrani, Meera Sridharan
Publikováno v:
Blood
Introduction: In patients with SARS-CoV-2 COVID-19 infection elevated D-dimers are associated with a poor prognosis. Although suggestive of DIC, the majority of patients do not fulfil ISTH criteria for DIC. Studies have demonstrated that when compare
Autor:
Robert L. Schmidt, Thomas B. Martins, Nahla M. Heikal, Rohan Willis, D. Ware Branch, Sandra K White, Anne E. Tebo
Publikováno v:
American journal of clinical pathology. 152(5)
Objectives Anti-β2 glycoprotein I domain I (anti-domain I) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies are present in patients with antiphospholipid syndrome (APS); however, their use in evaluation remains unclear. Methods Diagnostic